{"id":"W4405276065","doi":"10.1200/jco-24-01278","title":"Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Dacarbazine; Medicine; Vinblastine; Nivolumab; Hodgkin lymphoma; Brentuximab vedotin; Oncology; Lymphoma; Doxorubicin; Bleomycin; Internal medicine; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001032495,0.0007266028,0.0009598447,0.0002396748,0.0002612757,0.0006141526,0.0005155668,0.0006241575,0.002169025],"category_scores_gemma":[0.0004661952,0.000337467,0.0005365648,0.000210755,0.0003880772,0.0004365293,0.000215992,0.001438103,0.0004763726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006393751,"about_ca_system_score_gemma":0.0008465734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007174142,"about_ca_topic_score_gemma":0.002984,"domain_scores_codex":[0.9997868,0.0001080289,0.00001390433,0.00003654935,0.00001870217,0.00003595845],"domain_scores_gemma":[0.9996551,0.00004241631,0.00006396937,0.00001995144,0.00002450921,0.0001939603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6990045,0.0584372,0.02349651,0.001361125,0.001788508,0.000366125,0.0004637377,0.002020602,0.04629417,0.0001994186,0.003868928,0.1626991],"study_design_scores_gemma":[0.6685864,0.2986851,0.02449078,0.00006921514,0.0005643422,0.0003153358,0.00007665459,0.001139923,0.002381324,0.0001042887,0.003568882,0.00001779812],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947449,0.002366293,0.0002195612,0.0002058173,0.00007823658,0.001161649,0.0004163373,0.00003811666,0.0007691276],"genre_scores_gemma":[0.9936992,0.001410689,0.0009033597,0.000595195,0.0001210533,0.000973482,0.001026462,0.000009843345,0.001260773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002169025,"threshold_uncertainty_score":0.007256091,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05430527939270365,"score_gpt":0.4388216268053439,"score_spread":0.3845163474126402,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}